Soulen, Michael C. http://orcid.org/0000-0001-8136-2123
Teitelbaum, Ursina R.
Mick, Rosemarie
Eads, Jennifer
Mondschein, Jeffrey I.
Dagli, Mandeep
van Houten, Diana
Damjanov, Nevena
Schneider, Charles
Cengel, Keith
Metz, David C.
Article History
Received: 4 August 2023
Accepted: 31 October 2023
First Online: 6 December 2023
Declarations
:
: Dr. Soulen reports grants and personal fees from Guerbet LLC, personal fees from Genetech, grants from Pfizer, grants from Sirtex, personal fees from AstraZeneca, personal fees from Varian, outside the submitted work. Dr. Eads reports grants from Oncolys, Genentech, Merck, Seagen, Medimmune, AstraZeneca, Arcus, Amgen, Gilead, and Hutchmed and personal fees from Advanced Accelerator Applications, outside the reported work. The remaining authors report no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study has obtained IRB approval from the University of Pennsylvania and the need for informed consent was waived. For this type of study, consent for publication is not required.